A Research Study Looking at New Protein-based Tablets in Healthy Men - Oral Formulation III
Status:
Completed
Trial end date:
2024-03-27
Target enrollment:
Participant gender:
Summary
In this study, a known medicine called 'semaglutide' will be tested in two different tablet
versions. The two tablets differ in the way these have been manufactured. The aim of the
study is to investigate the amount of active ingredient in the blood after dosing the
different tablet versions. Participants will receive one tablet version for 10 days (first
treatment period) and the other version for 10 days (second treatment period). The treatment
arm participants will be assigned to is decided by chance. The study will last for about 23
weeks for each participant. The study will enroll healthy male participants.